Monocyte/macrophage response to β2-microglobulin modified with advanced glycation end products

This publication has 33 references indexed in Scilit:

• Is β2-microglobulin a mediator of bone disease?
  Kidney International, 1995
• Glycation of Human .beta.2-Microglobulin in Patients with Hemodialysis-Associated Amyloidosis: Identification of the Glycated Sites
  Biochemistry, 1994
• beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis.
  Journal of Clinical Investigation, 1993
• Effect of dialysis membrane and patient's age on signs of dialysis-related amyloidosis
  Kidney International, 1991
• Role of Oxidative Stress in Development of Complications in Diabetes
  Diabetes, 1991
• Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging.
  Proceedings of the National Academy of Sciences, 1990
• Cachectin/TNF and IL-1 Induced by Glucose-Modified Proteins: Role in Normal Tissue Remodeling
  Science, 1988
• Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic Complications
  New England Journal of Medicine, 1988
• Polymerization of intact beta 2-microglobulin in tissue causes amyloidosis in patients on chronic hemodialysis.
  Proceedings of the National Academy of Sciences, 1986
• A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin
  Biochemical and Biophysical Research Communications, 1985